Europe News
Filter News
Found 94,366 articles
-
Research seems to concur that a person who has recovered from severe COVID-19 symptoms might experience cognitive function and memory loss later on.
-
BioSpace Movers & Shakers, July 30, 2021
7/30/2021
Biopharma and life science companies strengthen their leadership teams and boards with these Movers & Shakers. -
Stilla Technologies Strengthens Executive Team with Appointment of Matthew Grow, PhD, to Vice President Global Marketing and Commercial Operations
7/30/2021
Life Sciences Veteran to Lead Commercialization of Disruptive Digital PCR Technology for a Broad Range of Basic Research and Clinical Applications.
-
Revolo Biotherapeutics Announces Clinical Trial Authorization to Initiate Phase 2 Trial of ‘1104 in Allergic Disease in the UK
7/30/2021
Revolo Biotherapeutics (“Revolo Bio” or the “Company”), announced today receipt of Clinical Trial Authorization (CTA) by the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK to evaluate safety and efficacy of its first-in-class peptide for the treatment of allergic disease, ‘1104, in a Phase 2 allergen sensitivity study.
-
ENYO Pharma Announces 16 Weeks Vonafexor (EYP001) Top-Line Interim Results from Two on-going Phase 2a Studies in Chronic Hepatitis B Patients
7/30/2021
ENYO Pharma, a private clinical stage biotechnology company developing innovative drug candidates, announced positive proof of concept data from Study EYP001-203 of Vonafexor in combination with pegylated-Interferon in viremic patients with chronic hepatitis B. Vonafexor met the primary endpoint of lowering HBsAg by an average of ≥ 1 log10, a key biomarker of viral activity in the liver, after 16 weeks of treatment.
-
Affimed Announces Publication of Comprehensive Preclinical Data Demonstrating the Therapeutic Potential of AFM24 in EGFR-expressing Tumors
7/30/2021
Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced the publication of a comprehensive preclinical in vitro and in vivo data package of its innate cell engager AFM24 in mAbs.
-
Change in number of shares and votes in Vitrolife AB (publ)
7/30/2021
In accordance with the decision at the board meeting on 8 July 2021, Vitrolife AB has issued a total of 9,645,303 new shares.
-
Eisai presented latest data from the lecanemab clinical program at AAIC 2021
7/30/2021
BioArctic AB's partner Eisai held several presentations at the Alzheimer's Association International Conference in Denver, Colorado July 26 to 30, 2021.
-
Small Pharma Reports First Fiscal Quarter 2021 Highlights
7/30/2021
Small Pharma Inc. (TSXV: DMT) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted N,N-dimethyltryptamine (“DMT”) therapies, has today published its first quarter results for the three months ended May 31, 2021.
-
Pharvaris Reports Second Quarter 2021 Financial Results and Provides Business Highlights
7/30/2021
Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today reported financial results for the second quarter ended June 30, 2021, and provided an update on recent business highlights.
-
Future of AstraZeneca’s Vaccine Business is Murky, But Seeks to Move Ahead with FDA Filing
7/29/2021
AstraZeneca said in an earnings announcement on Thursday it will seek authorization for its COVID-19 vaccine in the U.S. sometime in the second half of this year. -
Pfizer has reported several highlights regarding its mRNA COVID-19 vaccine. As the world deal with rising Delta variant cases, Pfizer-BioNTech is still arguing that a third booster shot will be likely.
-
COVID News: EUA Expanded for Baricitinib, Emergent Starts to Manufacture J&J Vaccine Again and More
7/29/2021
As COVID-19 infections continue to increase in the U.S., the FDA has expanded the EUA for Eli Lilly’s monoclonal antibody to include treatment with or without remdesivir. -
Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations including Takeda, Origin Therapeutics, ERS Genomics and more.
-
NRG Therapeutics Awarded $500K Grant from The Michael J. Fox Foundation to Progress Parkinson’s Programme
7/29/2021
NRG Therapeutics Ltd (“NRG” or “company”), an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announced that it has been awarded a $500,000 grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF), to support its lead drug discovery programme and the development of a novel treatment for Parkinson’s.
-
GSK announces FDA approval for Nucala (mepolizumab) for use in adults with chronic rhinosinusitis with nasal polyps
7/29/2021
GlaxoSmithKline plc (GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as a treatment for patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
-
Strategic Partnership Between Genedata and SCIEX Deepens and Accelerates Characterization of Next Generation Biotherapeutics
7/29/2021
SCIEX, a global leader in life science analytical technologies, and Genedata, leading provider of biopharma enterprise software solutions, have entered into a strategic partnership to develop new software solutions for the biopharmaceutical mass spectrometry market.
-
Swedish company ZandCell offers Russia 750 million dose vaccine capacity for Sputnik V and Aurora
7/29/2021
ZandCell, a biotech company with a proven track record in immunotherapies and COVID-19 diagnostics is announcing that it wants to manufacture the Russian vaccines for worldwide distribution.
-
ERYTECH Granted U.S. FDA Fast Track Designation for Eryaspase in Hypersensitive ALL
7/29/2021
ERYTECH Pharma (Nasdaq & Euronext: ERYP),a clinical-stage biopharmaceutical company, leader in red blood-cell based cancer therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL)patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).
-
KORTUC Inc. Closed Financing From AXA Japan to Accelerate Pivotal Phase II Study of Novel Radiosensitizer for Cancer Radiotherapy
7/29/2021
Today KORTUC Inc., a Japanese clinical-stage biopharmaceutical company focusing on the clinical and product development of a novel radiosensitizer improving the effectiveness of cancer radiotherapy (RT), announces the closing of an equity investment from AXA Japan.